Enhancement of transport of therapeutic molecules across the blood brain barrier
US9676849B2 · kind B2 · utility
8Cited by
0References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2013 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Jan 10, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., the TMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 VHH. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.